Brief: PureTech Founded Vedanta Biosciences Announces Phase 2 Study Of Ve202 Did Not Meet Primary Endpoint

Puretech Health

13/08/2025 17:32

Aug 13 (Reuters) - PureTech Health PLC PRTC.L:

PURETECH FOUNDED ENTITY VEDANTA BIOSCIENCES ANNOUNCES PHASE 2 STUDY OF VE202 IN ULCERATIVE COLITIS DID NOT MEET PRIMARY ENDPOINT

Source text: ID:nBwWbJWga

Further company coverage: PRTC.L

 ((Reuters.Briefs@thomsonreuters.com;))